Milestone Payment Amount Clause Samples
Milestone Payment Amount. Filing of an NDA with the FDA (or foreign equivalent) for a clinical indication covered by a Valid Claim. * Approval by the FDA (or foreign equivalent) of the marketing of a Product addressing clinical indication covered by a Valid Claim (“FDA Approval”); *
Milestone Payment Amount. (a) Definitions Related to Milestones.
Milestone Payment Amount. Upon satisfaction of both of the following conditions: (i) administration of the first dose in the first Phase III Clinical Trial of the Lead Product and (ii) at least [* *] of the investigator sites for such Phase III Clinical Trial have been approved by the applicable IRB and are drug receivable [* *]
Milestone Payment Amount. In partial consideration of the licenses and other rights granted by Nektar to Daiichi Sankyo under this Agreement, and subject to Section (b) below, Daiichi Sankyo shall pay Nektar upon the first achievement of the applicable milestone event described in the table below; provided however, [***]. Each of the milestone payments hereunder is non-creditable, non-refundable and not subject to set-off.
Milestone Payment Amount. (a) The Milestone Payment Amount shall be: Milestone Payment Amount = MPX +
Milestone Payment Amount. The first administration of a subject in a Phase 1a Clinical Trial of any Licensed Technology, Licensed Compound or Licensed Product. [***]U.S. Dollars (US$[***]) at Licensee’s sole and absolute discretion in either cash and/or Common Stock (or any combination thereof) with such Common Stock being valued on the third (3rd) Trading Day after the Public Announcement of such milestone event. The first administration to a patient in a Phase 1b Clinical Trial or Phase 2 Clinical Trial, whichever comes first of any Licensed Technology, Licensed Compound or Licensed Product. [***] U.S. Dollars (US$[***]), at Licensee’s sole and absolute discretion in either cash and/or Common Stock (or any combination thereof) with such Common Stock being valued on the third (3rd) Trading Day after the Public Announcement of such milestone event. The completion of the first Phase 2 Clinical Trial which meets its primary endpoint of statistical significant efficacy allowing the Parties to proceed with the first Phase 3 Clinical Trial of any Licensed Technology, Licensed Compound or Licensed Product. [***] U.S. Dollars (US$[***]) at Licensee’s sole and absolute discretion in either cash and/or Common Stock (or any combination thereof), with such Common Stock being valued on the third (3rd) Trading Day after the Public Announcement of such milestone event.